European Journal of Chemistry 2010, 1(4), 325-334 | doi: https://doi.org/10.5155/eurjchem.1.4.325-334.195 | Get rights and content






  OPEN ACCESS | PEER-REVIEWED | RESEARCH ARTICLE | DOWNLOAD PDF | VIEW FULL-TEXT PDF | TOTAL VIEWS

QSAR rationales for the 1,2-diarylcyclopentenes as prostaglandin EP1 receptor antagonists: Potentially useful in the treatment of inflammatory pain


Brij Kishore Sharma (1,*) , Pradeep Pilania (2) , Prithvi Singh (3)

(1) Department of Chemistry, Shri Kalyan Government College, Sikar, IN-332001, India
(2) Department of Chemistry, Shri Kalyan Government College, Sikar, IN-332001, India
(3) Department of Chemistry, Shri Kalyan Government College, Sikar, IN-332001, India
(*) Corresponding Author

Received: 06 Jul 2010 | Revised: 28 Aug 2010 | Accepted: 01 Sep 2010 | Published: 22 Dec 2010 | Issue Date: December 2010

Abstract


The EP1 receptor inhibitory activity of 1,2-diarylcyclopentene derivatives have been quantitatively analyzed in terms of Dragon descriptors. The derived QSAR models have provided rationales to explain the EP1 receptor inhibitory activity of 1,2-diarylcyclopentene derivatives. The 2D-autocorrelation descriptors (MATS4e, MATS5e, MATS7v, GATS5e and GATS7v) have highlighted the role of atomic properties in respective lags of autocorrelations to explain the biological actions of 1,2-diarylcyclopentene analogues. Presence of fluorine atom (nF) and smaller distance between N and O atoms (T(N..O)) in molecular structures, in addition to Kier-Hall electrotopological states (Ss) have also shown prevalence to optimize the EP1 receptor inhibitory activity. Partial least square analysis has confirmed the dominance of information content of the combinatorial protocol in multiple linear regression identified descriptors. Applicability domain analysis revealed that the suggested model matches the high quality parameters with good fitting power and capability of assessing external data. All the compounds are within the applicability domain of the proposed model and were evaluated correctly.

1_4_325_334_800


Keywords


1,2-Diarylcyclopentenes; EP1 receptor antagonists; Dragon descriptors; QSAR; CP-MLR; Partial least square analysis

Full Text:

PDF /    /


DOI: 10.5155/eurjchem.1.4.325-334.195

Links for Article


| | | | | | |

| | | | | | |

Related Articles




Article Metrics

This Abstract was viewed 683 times | PDF Article downloaded 353 times


Citations

/


[1]. Tawassl Tajelsir Hassan Hajalsiddig, Ahmed Elsadig Mohammed Saeed
QSAR and molecular docking studies on 4-quinoline carboxylic acid derivatives as inhibition of vesicular stomatitis virus replication
European Journal of Chemistry  10(1), 45, 2019
DOI: 10.5155/eurjchem.10.1.45-51.1795
/


[2]. Mukesh C. Sharma, Smita Sharma, Shivangi Sharma
Computational study of diarylcyclopentene derivatives as selective prostaglandin EP1 receptor antagonist: QSAR approach
Network Modeling Analysis in Health Informatics and Bioinformatics  5(1), , 2016
DOI: 10.1007/s13721-016-0120-y
/


References

[1]. Murakami, M.; Nakatani, Y.; Tanioka, T.; Kudo, I. Prostaglandins Other Lipid Mediat. 2002, 68-69, 383-399.
doi:10.1016/S0090-6980(02)00043-6

[2]. Claveau, D.; Sirinyan, M.; Guay, J.; Gordon, R.; Chan, C-C.; Bureau, Y.; Riendeau, D.; Mancini, J. A. J. Immunol. 2003, 170, 4738-4744.

[3]. Trebino, C. E.; Stock, J. L.; Gibbons, C. P.; Naiman, B. M.; Wachtmann, T. S.; Umland, J. P.; Pandher, K.; Lapointe, J-M.; Saha, S.; Roach, M. L.; Carter, D.; Thomas, N. A.; Durtschi, B. A.; McNeish, J. D.; Hambor, J. E.; Jakobsson, P-J.; Carty, T. J.; Perez J. R.; Audoly, L. P. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 9044-9049.
doi:10.1073/pnas.1332766100
PMid:12835414    PMCid:166435

[4]. Kamei, D.; Yamakawa, K.; Takegoshi, Y.; Mikami-Nakanishi, M.; Nakatani, Y.; Oh-ishi, S.; Yasui, H.; Azuma, Y.; Hirasawa, N.; Ohuchi, K.; Kawaguchi, H.; Ishikawa, Y.; Ishii, T.; Uematsu, S.; Akira, S.; Murakami, M.; Kudo, I. J. Biol. Chem. 2004, 279, 33684-33695.
doi:10.1074/jbc.M400199200
PMid:15140897

[5]. Mabuchi, T.; Kojima, H.; Abe, T.; Takagi, K.; Sakurai, M.; Ohmiya, Y.; Uematsu, S.; Akira, S.; Watanabe, K.; Ito, S. Neuroreport 2004, 15, 1395-1398.
doi:10.1097/01.wnr.0000129372.89000.31
PMid:15194860

[6]. Camu, F.; Shi, L.; Vanlersberghe, C. Drugs 2003, 63(suppl. 1), 1-7.
doi:10.2165/00003495-200363001-00002
PMid:14506906

[7]. Bianchi, M.; Broggini, M. Drugs 2003, 63(suppl. 1), 37-46.
doi:10.2165/00003495-200363001-00006
PMid:14506910

[8]. Jeger, R. V.; Greenberg, J. D.; Ramanathan, K.; Farkouh, M. E. Exp. Rev. Clin. Immunol. 2005, 1, 37-45.
doi:10.1586/1744666X.1.1.37
PMid:20477653

[9]. Lee, Y.; Rodriguez, C.; Dionne, R. A. Curr. Pharm. Des. 2005, 11, 1737-1755.
doi:10.2174/1381612053764896
PMid:15892672

[10]. Akarca, U. S. Curr. Pharm. Des. 2005, 11, 1779-1793.
doi:10.2174/1381612053764904
PMid:15892675

[11]. Sheen, C. L.; MacDonald, T. M. Exp. Opin. Pharmacother. 2002, 3, 265-269.
doi:10.1517/14656566.3.3.265
PMid:11866677

[12]. Hawkey, C. J.; Jackson, L.; Harper, S. E.; Simon, T. J.; Mortensen, E.; Lines, C. R. Aliment. Pharmacol. Ther. 2001, 15, 1-9.
doi:10.1046/j.1365-2036.2001.00894.x

[13]. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; Davis, B.; Day, R.; Bosi Ferraz, M.; Hawkey, C. J.; Hochberg, M. C.; Kvien T. K.; Schnitzer, T. J.; VIGOR study group. N. Eng. J. Med. 2000, 343, 1520-1528.
doi:10.1056/NEJM200011233432103
PMid:11087881

[14]. Silverstein, F. E.; Faich, G.; Goldstein, J. L.; Simon, L. S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N. M.; Stenson, W. F.; Burr, A. M.; Zhao, W. W.; Kent, J. D.; Lefkowith, J. B.; Verburg, K. M.; Geis, G. S. J. Am. Med. Assoc. 2000, 284, 1247-1255.
doi:10.1001/jama.284.10.1247
PMid:10979111

[15]. Merck & Co. Press Release; 30 September 2004. http://www.merck.com.

[16]. Mukherjee, D.; Nissen, S. E.; Topol, E. J. J. Am. Med. Assoc. 2001, 286, 954-959.
doi:10.1001/jama.286.8.954
PMid:11509060

[17]. Mamdani, M.; Juurlink, D. N.; Lee, D. S.; Rochon, P. A.; Kopp, A.; Naglie, G.; Austin, P. C.; Laupacis, A.; Stukel, T. A. Lancet 2004, 363, 1751-1756.
doi:10.1016/S0140-6736(04)16299-5

[18]. Scheen, A. J. Rev. Med. Liege 2004, 59, 565-569.
PMid:15623076

[19]. Bresalier, R. S.; Sandier, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M. A.; Baron, J. A. N. Engl. J. Med. 2005, 352, 1092-1102.
doi:10.1056/NEJMoa050493
PMid:15713943

[20]. Solomon, S. D.; McMurray, J. J. V.; Pfeffer, M. A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W. F.; Zauber, A.; Hawk E.; Bertagnolli, M. N. Engl. J. Med. 2005, 352, 1071-1080.
doi:10.1056/NEJMoa050405
PMid:15713944

[21]. Fitzgerald, G. A. N. Engl. J. Med. 2004, 351, 1709-1711.
doi:10.1056/NEJMp048288
PMid:15470192

[22]. Lagakos, S. W. N. Engl. J. Med. 2006, 355, 113-117.
doi:10.1056/NEJMp068137
PMid:16801354

[23]. Meagher, E. A. Curr. Pharm. Des. 2004, 10, 603-611.
doi:10.2174/1381612043453153
PMid:14965323

[24]. Coleman, R. A.; Smith, W. L.; Narumiya, S. Pharmacol. Rev. 1994, 46, 205-229.
PMid:7938166

[25]. Breyer, R. M.; Bagdassarian, C. K.; Myers, S. A.; Breyer, M. D. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 661-690.
doi:10.1146/annurev.pharmtox.41.1.661
PMid:11264472

[26]. Narumiya, S.; Sugimoto, Y.; Ushikubi, F. Physiol. Rev. 1999, 79, 1193-1226.
PMid:10508233

[27]. Coleman, R. A.; Kennedy, I.; Humphrey, P. P. A.; Bunce, K.; Lumley, P. Comprehensive Medicinal Chemistry, 3rd volume, Pergamon: Oxford, UK, 1990.

[28]. Hata, A. N.; Breyer, R. M. Pharmacol. Ther. 2004, 103, 147-166.
doi:10.1016/j.pharmthera.2004.06.003

[29]. Ungrin, M. D.; Carrière, M-C.; Denis, D.; Lamontagne, S.; Sawyer, N.; Stocco, R.; Tremblay, N.; Metters, K. M.; Abramovitz, M. Mol. Pharmacol. 2001, 59, 1446–1455.
PMid:11353805

[30]. Hallinan, E.; Hagen, T.; Jusa, R.; Tsymbalov, S.; Rao, S.; van Hoeck, J-P.; Rafferty, M.; Stapelfeld, A.; Savage, M.; Reichman, M. J. Med. Chem. 1993, 36, 3293-3299.
doi:10.1021/jm00074a010
PMid:7901416

[31]. Hallinan, E.; Stapelfeld, A.; Savage, M.; Reichman, M. Bioorg. Med. Chem. Lett. 1994, 4, 509-514.
doi:10.1016/0960-894X(94)80027-8

[32]. Lanthorn, T.; Bianchi, R.; Perkins, W. Drug Dev. Res. 1995, 34, 35–38.
doi:10.1002/ddr.430340106

[33]. Novel EP1 receptor antagonists. Expert Opin. Ther. Patents 2004, 14, 435-438.

[34]. Breault, G.A. WO9700863A1, 1997.

[35]. Watanabe, K.; Kawamori, T.; Nakatsugi, S.; Ohta, T.; Ohuchida, S.; Yamamoto, H.; Maruyama, T.; Kondo, K.; Narumiya, S.; Sugimura, T.; Wakabayashi, K. Cancer Lett. 2000, 156, 57-61.
doi:10.1016/S0304-3835(00)00440-7

[36]. Ducharme, Y.; Blouin, M.; Carrière, M. C.; Chateauneuf, A.; Côte, B.; Denis, D.; Frenette, R.; Greig, G.; Kargman, S.; Lamontagne, S.; Martins, E.; Nantel, F.; O’Neill, G.; Sawyer, N.; Metters, K. M.; Friesen, R. W. Bioorg. Med. Chem. Lett. 2005, 15, 1155-1160.
doi:10.1016/j.bmcl.2004.12.005

[37]. Minami, T.; Nakano, H.; Kobayashi, T.; Sugimoto, Y.; Ushikubi, F.; Ichikawa, A.; Narumiya, S.; Ito, S. Br. J. Pharmacol. 2001, 133, 438-444.
doi:10.1038/sj.bjp.0704092
PMid:11375261    PMCid:1572799

[38]. Mebane, H.; Turnbach, M. E.; Randich, A. J. Pain 2003, 4, 392-399.
PMid:11160156    PMCid:199184

[39]. Stock, J. L.; Shinjo, K.; Burkhardt, J.; Roach, M.; Taniguchi, K.; Ishikawa, T.; Kim, H-S.; Flannery, P. J.; Coffman, T. M.; McNeish, J. D.; Audoly, L. P. J. Clin. Invest. 2001, 107, 325-331.
doi:10.1172/JCI6749

[40]. Omote, K.; Kawamata, T.; Nakayama, Y.; Kawamata, M.; Hazama, K.; Namiki, A. Anesth. Analg. 2001, 92, 233-238.
doi:10.1097/00000539-200101000-00045

[41]. Omote, K.; Yamamoto, H.; Kawamata, T.; Nakayama, Y.; Namiki, A. Anesth. Analg. 2002, 95, 1708-1712.
doi:10.1097/00000539-200212000-00044

[42]. Kawahara, H.; Sakamoto, T.; Takeda, S.; Onodera, H.; Imaki, J.; Ogawa, R. Anesth. Analg. 2001, 93, 1012-1017.
doi:10.1097/00000539-200110000-00043

[43]. Giblin, G. M. P.; Bit, R. A.; Brown, S. H.; Chaignot, H. M.; Chowdhury, A.; Chessell, I. P.; Clayton, N. M.; Coleman, T.; Hall, A.; Hammond, B.; Hurst, D. N.; Michel, A. D.; Naylor, A.; Novelli, R.; Scoccitti, T.; Spalding, D.; Tang, S. P.; Wilson, A. W.; Wilson, R. Bioorg. Med. Chem. Lett. 2007, 17, 385-389.
doi:10.1016/j.bmcl.2006.10.041

[44]. SYSTAT, Version 7.0; SPSS Inc., 444 North Michigan Avenue, Chicago, IL, 60611.

[45]. ChemDraw Ultra 6.0 and Chem3D Ultra, Cambridge Soft Corporation, Cambridge, USA. http://www.cambridgesoft.com

[46]. Dragon software (version 1.11-2001) by Todeschini R.; Consonni V. Milano, Italy. http://www.talete.mi.it/dragon.htm

[47]. Prabhakar, Y. S. QSAR Comb. Sci. 2003, 22, 583-595.
doi:10.1002/qsar.200330814

[48]. Wold, S. Technometrics 1978, 20, 397-405.
doi:10.2307/1267639

[49]. Kettaneh, N.; Berglund, A.; Wold, S. Comput. Stat. Data Anal. 2005, 48, 69-85.
doi:10.1016/j.csda.2003.11.027

[50]. Stahle, L.; Wold, S. Biomedical Research, Progress in Medicinal Chemistry, vol. 25, Elsevier Science Publishers, BV, 1998.

[51]. Sharma, B. K.; Pilania, P.; Singh, P.; Sharma, S.; Prabhakar, Y. S. Cent. Eur. J. Chem. 2009, 7, 909-922.
doi:10.2478/s11532-009-0073-4
PMid:18825552

[52]. Sharma, B. K.; Pilania, P.; Singh, P. J. Enz. Inhib. Med. Chem. 2009, 24, 607-615.
doi:10.1080/14756360802318878
PMid:19548781

[53]. Sharma, S.; Sharma, B. K.; Pilania, P.; Singh, P.; Prabhakar, Y. S. J. Enz. Inhib. Med. Chem. 2009, 24, 1024-1033.
doi:10.1080/14756360802608054
PMid:20373219

[54]. Sharma, B. K.; Pilania, P.; Singh, P.; Prabhakar, Y. S. SAR QSAR Environ. Res. 2010, 21, 169-185.
doi:10.1080/10629360903570545
PMid:19657719

[55]. Sharma, B. K.; Pilania, P.; Sarbhai, K.; Singh, P.; Prabhakar, Y. S. Mol. Divers. 2010, 14, 371-384.
doi:10.1007/s11030-009-9181-5

[56]. Akaike, H. Second international symposium on information theory, Akademiai Kiado, Budapest, 1973.

[57]. Akaike, H. IEEE Trans. Automat. Contr. 1974, AC-19, 716-723.
doi:10.1109/TAC.1974.1100705

[58]. Kubinyi, H. Quant. Struct.-Act. Relat. 1994, 13, 285-294.

[59]. Kubinyi, H. Quant. Struct.-Act. Relat. 1994, 13, 393-401.
PMid:9435904

[60]. Friedman, J. Technical report no. 102. Laboratory for computational statistics. Stanford University, Stanford, 1990.

[61]. So, S. -S.; Karplus, M. J. Med. Chem. 1997, 40, 4347-4359.
doi:10.1021/jm970487v

[62]. Prabhakar, Y. S.; Solomon, V. R.; Rawal, R. K.; Gupta, M. K.; Katti, S. B. QSAR Comb. Sci. 2004, 23, 234-244.
doi:10.1002/qsar.200330854

[63]. Gramatica, P. QSAR Comb. Sci. 2007, 26, 694-701.
doi:10.1002/qsar.200610151

[64]. Golbraikh, A.; Tropsha, A. J. Mol. Graph. Model. 2002, 20, 269-276.
doi:10.1016/S1093-3263(01)00123-1

How to cite


Sharma, B.; Pilania, P.; Singh, P. Eur. J. Chem. 2010, 1(4), 325-334. doi:10.5155/eurjchem.1.4.325-334.195
Sharma, B.; Pilania, P.; Singh, P. QSAR rationales for the 1,2-diarylcyclopentenes as prostaglandin EP1 receptor antagonists: Potentially useful in the treatment of inflammatory pain. Eur. J. Chem. 2010, 1(4), 325-334. doi:10.5155/eurjchem.1.4.325-334.195
Sharma, B., Pilania, P., & Singh, P. (2010). QSAR rationales for the 1,2-diarylcyclopentenes as prostaglandin EP1 receptor antagonists: Potentially useful in the treatment of inflammatory pain. European Journal of Chemistry, 1(4), 325-334. doi:10.5155/eurjchem.1.4.325-334.195
Sharma, Brij, Pradeep Pilania, & Prithvi Singh. "QSAR rationales for the 1,2-diarylcyclopentenes as prostaglandin EP1 receptor antagonists: Potentially useful in the treatment of inflammatory pain." European Journal of Chemistry [Online], 1.4 (2010): 325-334. Web. 23 Sep. 2020
Sharma, Brij, Pilania, Pradeep, AND Singh, Prithvi. "QSAR rationales for the 1,2-diarylcyclopentenes as prostaglandin EP1 receptor antagonists: Potentially useful in the treatment of inflammatory pain" European Journal of Chemistry [Online], Volume 1 Number 4 (22 December 2010)

The other citation formats (EndNote | Reference Manager | ProCite | BibTeX | RefWorks) for this article can be found online at: How to cite item


DOI Link: https://doi.org/10.5155/eurjchem.1.4.325-334.195

| | | | | | |

| | | | | |

Save to Zotero Save to Mendeley



European Journal of Chemistry 2010, 1(4), 325-334 | doi: https://doi.org/10.5155/eurjchem.1.4.325-334.195 | Get rights and content

Refbacks

  • There are currently no refbacks.




Copyright (c)




© Copyright 2010 - 2020  Atlanta Publishing House LLC All Right Reserved.

The opinions expressed in all articles published in European Journal of Chemistry are those of the specific author(s), and do not necessarily reflect the views of Atlanta Publishing House LLC, or European Journal of Chemistry, or any of its employees.

Copyright 2010-2020 Atlanta Publishing House LLC. All rights reserved. This site is owned and operated by Atlanta Publishing House LLC whose registered office is 2850 Smith Ridge Trce Peachtree Cor GA 30071-2636, USA. Registered in USA.